Previous 10 | Next 10 |
There are a lot of promising stocks out there for investors to choose from. However, if you're looking for companies with the most growth potential, the world of small-cap stocks is one of the best places to look. In particular, biotech stocks are very well known for having tremendous upside ...
Puma Biotechnology ( PBYI ) recently publicized their Q4/2019 earnings that revealed a strong beat in both EPS and revenue. Puma reported total revenue for the fourth quarter of 2019 of $62.9M. Total product revenue consisted of license revenue of $4M, royalty revenue of $0.2M and net sale...
Aside from an acquisition, earning marketing approval for a drug candidate is the single biggest event that can happen for a development-stage pharmaceutical company. It marks the beginning of the transition to commercial operations and tends to spark a celebration among investors. But sometimes...
February 27, 2020 Palm Beach, FL – February 27, 2020 – Globally, breast cancer effects 2.1 million women every year. In 2018 alone, it was the cause of nearly 627,000 deaths, according to the World Health Organization, accounting for 15% of all cancer deaths ...
SELLAS Life Sciences Group (NASDAQ: SLS ) +23% on positive follow-up phase 1/2 clinical data for Galinpepimut-S in acute myeloid leukemia. More news on: SELLAS Life Sciences Group, Inc., Alcon, Inc., Moderna, Inc., Stocks on the move, , Read more ...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic H...
The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2019 Q4 earnings Read more ...
TrueCar (NASDAQ: TRUE ) -29% after guidance disappoints. More news on: TrueCar, Inc., BlueLinx Holdings Inc., EyePoint Pharmaceuticals, Inc., Stocks on the move, , Read more ...
Puma Biotechnology ( PBYI ) Q4 results : More news on: Puma Biotechnology, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Image source: The Motley Fool. Puma Biotechnology Inc (NASDAQ: PBYI) Q4 2019 Earnings Call Feb 20, 2020 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...